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Objective. Endovenous laser ablation (EVLA) is an alternative to surgery for treating sapheno-femoral and great saphe-
nous vein (GSV) reflux. This study assesses factors that might influence its effectiveness.
Design. Prospective, observational study.
Method. EVLA was used to treat the great saphenous vein in 644 limbs as part of the management of varicose veins. Body
mass index (BMI), maximum GSV diameter, length of vein treated, total laser energy (TLE) and energy density (ED:
Joules/cm) delivered were recorded prospectively. Data from limbs with ultrasound confirmed GSV occlusion at 3-months
were compared with those where the GSV was partially occluded or patent. Complications were recorded prospectively.
Results. GSV occlusion was achieved in 599/644 (93%) limbs (group A). In 45 limbs (group B) the vein was partially
occluded (n¼ 19) or patent (n¼ 26). Neither BMI [group A: 25.2 (23.0e28.5); group B: 25.1 (24.3e26.2)], nor GSV di-
ameter [A: 7.2 mm (5.6e9.2); B: 6.9 mm (5.5e7.7)] influenced success. TLE and ED were greater p< 0.01) in group A
(median [inter-quartile range]: 1877 J (997e2350), 48 (37e59) J/cm) compared to group B (1191 J (1032e1406), 37 (30e
46) J/cm). Although TLE reflects the greater length of GSV ablated in Group A (33 cm v 29 cm, p¼ 0.06) this does not
influence ED. GSV occlusion always occurred when ED 60 J/cm with no increase in complications.
Conclusions. ED (J/cm) of laser delivery is the main determinant of successful GSV ablation following EVLA.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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factors.Introduction
Endovenous laser ablation (EVLA) is a relatively new
minimally invasive treatment for varicose veins and
can be used to abolish reflux from the sapheno-femoral
(SFC) or sapheno-popliteal confluence (SPC) and the
associated axial vein (great saphenous vein [GSV],
small saphenous vein [SSV]). Successful treatment de-
pends upon elimination of the highest point of ‘‘deep
to superficial’’ incompetence and ablation of the in-
competent axial vein.1e7 EVLA aims to achieve selec-
tive ablation of the incompetent GSV and eliminate
both GSV and SFC reflux. Previous studies indicate
that ablation is achieved in 88e100% of limbs.8
Similar success rates are reported for radiofrequency
ablation (RFA)9e12 which causes endothelial denu-
dation, collagen denaturation and acute vein
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col for the treatment of all patients this is not the
case for EVLA. The power of the laser, the total energy
delivery and the amount of energy delivered/cm of
vein (energy density) are all under the control of the
operator although when introduced for clinical use
the manufacturer’s original advice was to use 12 watts
power to deliver around 48 J/cm vein. Nevertheless
few studies report 100% occlusion rates and the factors
that might influence this are not fully understood. This
observational study analyses those that could influ-
ence the effectiveness of EVLA with the aim of estab-
lishing a standardised protocol to ensure successful
ablation in as many patients as possible.
Methods
Patients
All patients attending the venous clinics of the Leeds
General Infirmary and the BUPA Hospital Leedslar Surgery. Published by Elsevier Ltd. All rights reserved.
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due to SFC and GSV reflux were evaluated by duplex
ultrasound to assess their suitability for EVLA. A por-
table duplex ultrasound system (TITAN, Sonosite
Inc, Bothell, USA) with a 5e10 MHz linear probe
was used to examine both the superficial and deep ve-
nous systems of the symptomatic limbs. Patients were
studied whilst standing. Using the colour flow facility
the presence of reflux was initially determined follow-
ing manual calf compression and release. Reflux dura-
tion of >1 s on the Doppler trace was considered
significant. When appropriate, EVLA was offered as
an alternative to surgery and patients were subse-
quently treated according to their preference. Those
who required ablation of an additional axial vein (an-
terior saphenous vein or SSV) or who were taking
warfarin were excluded from the study.
EVLA suitability
Suitability for EVLA depended upon a 10 cm rela-
tively straight segment of GSV immediately distal to
the SFC, an absence of significant varicosities arising
within 10 cm of the SFC, and a GSV diameter of
3 mm at the intended cannulation site (usually just
above the knee).
Standard laser technique
Under ultrasound guidance the GSV was cannulated
at or slightly above the level of knee using a Seldinger
technique. A guide wire was passed proximally into
the femoral vein and a 5F (1.67 mm) catheter was po-
sitioned under ultrasound control 0.5e1 cm distal to
the SFC. Perivenous tumescent local anaesthesia
(0.1% lignocaine, 150e200 ml) was infiltrated along
the vein under ultrasound guidance. A bare-tipped la-
ser fibre connected to an 810 nm diode laser source
was inserted via the catheter and then gradually with-
drawn so that 3e5 pulses of laser energy (12 Watts
power, 1 second pulses, 1 second intervals) were de-
livered/cm vein. Neither concomitant phlebectomies
nor foam sclerotherapy were used to treat varicosities
at the time of EVLA. Following treatment a non-
stretch compression bandage was applied to the
limb for 1 week followed by a class 2 support stocking
for a further week. Patients were prescribed 50 mg di-
clofenac sodium tds for 3 days to reduce inflamma-
tory ‘phlebitis’ of the GSV. Patients were encouraged
to resume their daily activities (including work) as
soon as possible.Eur J Vasc Endovasc Surg Vol 35, January 2008Follow-up
Patients were reviewed at 6 and 12 weeks. Treated
limbs were assessed clinically and by duplex ultra-
sound scanning. Those who had residual varicosities
with controlled axial reflux (occluded treated vein)
were offered foam sclerotherapy (sodium tetradecyl
sulphate) at the 6 week visit. Patients with persisting
significant reflux at any follow-up appointment were
offered a choice of either surgery or repeat EVLA.
Criteria for successful GSV ablation on ultrasound
were non-compressibility or disappearance of the
treated segment of vein together with absence of
flow on colour-flow duplex ultrasound and a compe-
tent SFC. Treatment failures were defined as veins
demonstrating flow and/or reflux in the treated GSV.
Data collection and analysis
Data were collected prospectively by 3 research fel-
lows and 2 consultant vascular surgeons trained in ve-
nous duplex ultrasound and recorded on a database.
The height and weight of patients (without footwear)
was measured on the day of treatment and used to
calculate the body mass index (BMI) of each patient.
The maximum diameter of the GSV was measured
using ultrasound (avoiding focal dilatations) while
standing and the length of vein treated (L) calculated
by reference to the 45 cm sheath used for laser fibre
insertion. The total laser energy (TLE) was directly ob-
tained (Joules) from the laser source after each treat-
ment enabling calculation of the energy density (ED,
J/cm). A prospective log of complications occurring
after EVLA was also maintained.
Two groups of patients were identified: those with
a full-length occlusion of the treated GSV and a com-
petent SFC (Group A) and those who had a patent or
partial occlusion of the axial vein, irrespective of their
clinical improvement and the reflux status of the SFC
(Group B).
Statistical analysis
Variables were compared between the two groups
using a student-t test (unpaired) and a chi-square test
employed to compare complication rates between the
groups. A ‘‘p’’ value of <0.05 was considered statisti-
cally significant. Data are presented as median (inter-
quartile range) unless stated otherwise. All analysis
were performed by statistical package SPSS for Win-
dows (SPSS (14), Chicago, Illinois, USA).
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582 patients (644 legs) have been followed-up for
a minimum of 3 months. Demographic data, includ-
ing the severity of the venous disease (CEAP) are
shown in Table 1. Group A comprised 599/644
(93%) limbs in which the most recent ultrasound
scan confirmed complete ablation of the treated
GSV. Of the remainder (Group B) the GSV was par-
tially occluded in 19/644 (3%) legs and patent in
26/644 (4%). The median energy density delivered
during ablation was 48 J/cm in Group A and 37 J/
cm in Group B. This difference was highly significant
( p< 0.01, t-test). These results, and other details about
the laser energy administered and data to support the
conclusion that BMI, maximum GSV diameter and the
length of vein ablated did not influence outcome are
summarised in Table 2.
AHosmer-Lemeshow goodness of fit test confirmed
good overall fitness of the model and a logistic regres-
sion analysis revealed that energy density is the single
most significant ( p¼ 0.001) predictor of the outcome.
The ED administered ranged from 22e82 J/cm and
this was used to sub-group the treated limbs (Table 3).
Regression analysis was performed on the graded ED
and the odds ratio (per grade of ED) was 0.49; 95% CI
0.36e0.67; p< 0.001. The frequency of successful abla-
tion was greater with increasing ED and when this
was 60 J/cm GSV ablation was achieved in all limbs
(100%). Importantly, a higher ED did not appear to in-
crease the rate of complications. In particular the fre-
quency of symptomatic ‘phlebitis’ in veins that
received 60 J/cm or <60 J/cm was 8% (7/86) and
11% (59/549) respectively ( p¼ 0.316).
In group A, 391 (65%) limbs were clinical class C2e
3 and 208 (36%) were C4e6. Similarly in group B, 31
(69%) limbs were C2e3 and 14 (31%) limbs were
C4e6. A Chi square test showed that the clinical se-
verity was similar in both groups ( p¼ 0.376) and
did not predict success or failure.
Table 1. Patient demography and disease severity scores
Number patients 582
Median age (range) 50 years (16e86)
Women 378 (65%)
Men 204 (35%)
Number of treated legs 644
Primary varicose veins 534/644 (83%)
Recurrent varicose veins 110/644 (17%)
C2 Varicose veins 361 (56%)
C3 Oedema 59 (9.2%)
C4 Skin changes 172 (26.7%)
C5 healed ulcer 33 (5.1%)
C6 active ulcer 19 (2.9%)
CEAP score: Clinical, Etiology, Anatomy, Pathology.Discussion
The findings of this study form the basis for develop-
ing a standardised protocol for successful EVLA. It is
clear that an ED of energy density 60 J/cm is central
to achieving complete GSV occlusion. This equates to
5 pulses/cm vein when using 12 watts power, 1 sec-
ond pulses and 1 second intervals for laser fibre with-
drawal i.e. 2 mm pull-back during each 1 s interval.
The choice of pulsed laser for EVLA was based on
the description of the technique and the results re-
ported by Min et al. in 2001.15 Continuous withdrawal
of the fibre using 14 watts power has also been advo-
cated (Min RJ, personal communication) although it
had not been suggested when patients were first re-
cruited to this database in 2002. This method has
now been adopted in our unit following confirmation,
in an unpublished prospective audit, that initial con-
cerns about both the efficacy of ablation (more rapid
withdrawal) and a possible increased risk of post-
treatment ‘‘phlebitis’’ or skin burns (higher power)
were unfounded. The principle benefit of continuous
withdrawal is a reduction in treatment time although
there is no evidence in the literature to suggest that
one technique is more effective than the other.
Delivery of 60 J/cm with continuous withdrawal
requires a pull-back rate of 1 cm of the laser fibre in
4.3 s. For practical purposes we have adopted a policy
of withdrawing 1 cm of fibre in 5 s equating to the de-
livery of 70 J/cm. Again we have found no evidence
of a higher complication rate when laser energy is de-
livered in this way.
Other authors have also assessed the efficacy en-
ergy delivery of different densities. Timperman re-
ported similar data to those presented here, with
a significant difference in laser energy delivery be-
tween ‘‘successes’’ and ‘‘failures’’ (63.4 J/cm versus
46.6 J/cm, p< 0.0001). In this study there were no
treatment failures with a laser dose of >80 J/cm14 al-
though in a subsequent study the same author treated
100 GSV with 95 J/cm achieving successful ablation in
95% of limbs.16 In contrast Kim et al. achieved 100%
technical success in 34 patients using a 980 nm diode
laser at 11 W power, delivering 35.16 J/cm.17 It is
likely that a small study such as this reflects either re-
porting bias or the less secure nature of such data
rather than a real finding.
Finally Proebstle et al. have produced data to sug-
gest that the energy delivery required to achieve reli-
able GSV ablation and low recanalisation rates is
dependent not only on the quantity of energy deliv-
ered but also on vein diameter. These workers con-
cluded that 6.3 J/cm of energy were required for
each mm GSV diameter for effective ablation. Thus,
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Variables Group A (n¼ 599) Group B (n¼ 45) ‘‘P’’ value
Total laser energy (J) 1877 (IQR 997e2350) 1191 (IQR 1032e1406) <0.05
Energy Density (J/cm) 48 (IQR 37e59) 37 (IQR 30e46) <0.01
Diameter of the vein* (mm) 7.2 (IQR 5.6e9.2) 6.9 (IQR 5.5e7.7) 0.28
BMI (Kg/m2) 25.2 (IQR 23.0e28.5) 25.1 (IQR 24.3e26.2) 0.36
Length of treated vein (cm) 33 (IQR 27e39) 29 (IQR 24e35) 0.06
Group A: limbs with complete occlusion of the treated GSV.
Group B: limbs with either a patent or partially occluded GSV.
*Maximum diameter measured whilst standing.for a 10 mm diameter vein this equates to 63 J/cm,
which is similar to the findings reported here.18 Since
this data was derived in from patients treated with la-
ser powers of 15 W or 30 W they are not necessarily
applicable to the more widely used technique em-
ploying 12e14 W power.
The same group have suggested that reporting en-
ergy delivery as J/cm is an oversimplification since it
does not take vein diameter into account. Thus Pro-
ebstle found that laser fluence (laser energy per cm2
vein) was a risk factor for non-occlusion19 and that
treatment regimes should be based upon this type of
calculation. Such an argument may be flawed since
vein diameter at the time of ablation is significantly
reduced due to catheter-induced spasm following
cannulation together with the effect of the tumescent
anaesthesia. Further, the vein may not be of a uniform
diameter throughout its length making the calculation
more difficult. The results of the present study sug-
gest that a protocol based on J/cm should be reliable
and easier to implement.
Although a protocol delivering 60 J/cm would be
straightforward it should be used with caution if the
vein for ablation is particularly superficial (within
<1 cm of skin surface). When this is the case care
should be taken to ensure that sufficient tumescent
anaesthesia is infiltrated between the vein and the
skin to prevent skin burns.
Although concern has also been voiced about the
risk of nerve injury in the popliteal fossa during
Table 3. Success of GSV occlusion and complications rate accord-














<30 82 71 86.6% 9 1 0
30e39.9 168 149 88.7% 16 2 0
40e49.9 176 164 93.2% 19 2 0
50e59.9 123 120 97.6% 15 1 1
60e69.9 79 79 100% 7 1 0
70 16 16 100% 0 0 0
Total 644 599 93% 66 (10.2%) 7 (1.1%) 1 (0.2%)Eur J Vasc Endovasc Surg Vol 35, January 2008EVLA a previous study from our unit has confirmed
that provided adequate volumes of tumescent anaes-
thesia are used the temperature 3 mm from the vein
does not reach the temperature (45 C) at which nerve
injury may occur when the energy density is 60 J/
cm.20 Furthermore the clinical results of SSV ablation
confirm that it can be performed safely at this level
of energy delvery.21
This study has also shown that neither vein diam-
eter nor the length of vein ablated had any influence
upon success rates and these findings are not particu-
larly surprising. The impact of BMI upon outcome
was also examined since the efficacy of post-EVLA
compression might have been reduced in obese pa-
tients. Although this did not seem to be an important
factor conflicting data have been reported by Timper-
man14 who found a statistically significant difference
in body mass index (BMI) between successes and fail-
ures (30 versus 46, p¼ 0.0009). This difference might
be explained by absence of significant numbers of
super-obese patients in our study.
Laser induces thermal injury to venous endothe-
lium and sub-endothelial collagen leading to fibrous
sclerosis of the vein.22e24 Although different wave
length diode lasers (808e1320 nm) have been used
for GSV ablation15,23e25 this study employed an
810 nm diode laser which proved to be safe, and effec-
tive, provided sufficient energy was used.
Successful EVLA depends upon inflicting sufficient
vein wall damage to cause contraction and subse-
quent fibrosis of the treated vein rather than thrombo-
sis which could lead to recanalisation and treatment
failure. In order to achieve this, factors other than
the quantum of thermal energy delivered to the vein
are likely to be important. Generous volumes of tu-
mescent anaesthesia and treatment in the Trendelen-
burg position should ensure that the vein is empty
and that the laser fibre is in close proximity to the
vein wall. This should increase the extent of irrevers-
ible damage to the vein wall. Further, it ensures that
the distribution of energy is more predictable and
not dependent upon vein diameter or the volume of
blood within the vein at the time of treatment.
123Factors Influencing the Effectiveness of EVLAIn conclusion this study has shown that the ED
(J/cm) of laser delivery is the main determinant of suc-
cessful GSVablationwith EVLA and delivery of60 J/
cm (810 nm diode laser (pulsed) at 12 W power) is re-
quired for optimum results. Neither GSV diameter
nor BMI appeared to influence outcome. Finally, the
frequency with which phlebitis occurred did not ap-
pear to be influenced by the energy density within
the study range.
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